Neogen Corporation

NEOG Healthcare Medical Devices

Neogen Corporation’s revenue for fiscal 2026 (year ended May 2026) was $870.4 million, down 2.72% from fiscal 2025.

Revenue
+6.50%
EPS
−129.4%
Free cash flow
+135.6%
Total debt
−2.31%

Quarter to August 2026, against a year earlier

11.72 0.04 +0.34%
Market cap
$2.6B
P/E
0.0×
Fwd P/E
−93.3×
Dividend yield
—
F-score
5/9
Altman Z
1.11
Beneish M
−2.43
Dividend safety
n/a

Neogen Corporation (NEOG) Debt to equity

Alert me on Debt to equity

Neogen Corporation's debt to equity at the end of the quarter to 31 August 2026 was 0.4×, down 0.0× from fiscal 2026 (0.4×). Over the past ten years it has ranged from 0.0× (fiscal 2019) to 0.4× (fiscal 2025); the current reading is higher than 92% of that period. That is above the Medical Devices industry median of 0.0× and above the Healthcare sector median of 0.0×.

Debt to equity, annual

Embed this chart

Annual newest first

Period Debt to equity Change
FY2026 0.4× (12.16%)
FY2025 0.4× 52.38%
FY2024 0.3× (0.07%)
FY2023 0.3× 25,672.73%
FY2022 0.0× (8.33%)
FY2021 0.0× (14.29%)
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —

Quarterly newest first

Period Debt to equity Change
Aug 2026 0.4× (2.14%)
May 2026 0.4× 0.50%
Feb 2026 0.4× 0.13%
Nov 2025 0.4× 0.72%
43 more quarters

Against its own ten years

Low 0.0× High 0.4×
Ten-year median 0.0×
Current reading's percentile 92

Debt to equity against peers

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on NEOG